Holen Sie sich die Stockscreener-App
431.21
0.93%
-4.06
Handel nachbörslich:
431.18
-0.03
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$435.27
Offen:
$436.3
24-Stunden-Volumen:
257.73K
Relative Volume:
0.69
Marktkapitalisierung:
$9.57B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-17.17
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
-1.36%
1M Leistung:
+38.16%
6M Leistung:
+34.20%
1J Leistung:
+75.76%
1-Tages-Spanne:
$426.00
$438.74
1-Wochen-Bereich:
$422.02
$443.00
52-Wochen-Spanne:
$200.63
$443.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
431.21 | 9.72B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Will Madrigal Pharmaceuticals Inc. see short term momentum2025 AllTime Highs & Low Risk Growth Stock Ideas - Newser
Analyzing Madrigal Pharmaceuticals Inc. with risk reward ratio charts2025 EndofYear Setup & AI Driven Stock Movement Reports - Newser
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewswire
How to forecast Madrigal Pharmaceuticals Inc. trends using time seriesJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - Newser
Analyzing net buyer seller activity in Madrigal Pharmaceuticals Inc.Market Activity Report & High Accuracy Investment Signals - Newser
Regression analysis insights on Madrigal Pharmaceuticals Inc. performanceEarnings Overview Report & Daily Technical Stock Forecast Reports - Newser
Will Madrigal Pharmaceuticals Inc. stock go up soonEarnings Miss & Smart Allocation Stock Reports - Newser
Intraday pattern recognizer results for Madrigal Pharmaceuticals Inc.July 2025 Trends & AI Driven Price Forecasts - Newser
Real time pattern detection on Madrigal Pharmaceuticals Inc. stockWeekly Trade Report & Low Drawdown Momentum Ideas - Newser
Is a relief rally coming for Madrigal Pharmaceuticals Inc. holdersQuarterly Trade Summary & Risk Managed Investment Signals - Newser
Key metrics from Madrigal Pharmaceuticals Inc.’s quarterly dataJuly 2025 News Drivers & Entry and Exit Point Strategies - Newser
Is Madrigal Pharmaceuticals Inc. affected by consumer sentiment2025 Key Lessons & Reliable Entry Point Trade Alerts - khodrobank.com
What are Madrigal Pharmaceuticals Inc.’s recent SEC filings showingWeekly Stock Analysis & Community Consensus Trade Signals - خودرو بانک
What is the target price for Madrigal Pharmaceuticals Inc. stockFed Meeting & Daily Growth Stock Investment Tips - khodrobank.com
Published on: 2025-09-02 10:53:17 - Newser
Published on: 2025-09-02 10:33:50 - Newser
Using Python tools to backtest Madrigal Pharmaceuticals Inc. strategiesJuly 2025 WrapUp & Advanced Swing Trade Entry Plans - Newser
Real time breakdown of Madrigal Pharmaceuticals Inc. stock performanceBull Run & Daily Stock Momentum Reports - Newser
How to manage a losing position in Madrigal Pharmaceuticals Inc.July 2025 Rallies & Verified Momentum Stock Ideas - Newser
Should you wait for a breakout in Madrigal Pharmaceuticals Inc.2025 Key Highlights & Capital Protection Trading Alerts - Newser
Can Madrigal Pharmaceuticals Inc. maintain sales growth2025 Earnings Impact & Daily Profit Focused Stock Screening - khodrobank.com
What machine learning models say about Madrigal Pharmaceuticals Inc.July 2025 Big Picture & Trade Opportunity Analysis - Newser
Trend analysis for Madrigal Pharmaceuticals Inc. this weekWatch List & Daily Chart Pattern Signals - Newser
Should you wait for a breakout in Madrigal Pharmaceuticals Inc2025 Key Lessons & AI Forecasted Entry and Exit Points - Newser
Is Madrigal Pharmaceuticals Inc. forming a bottoming baseJuly 2025 Retail & Real-Time Chart Pattern Alerts - Newser
Forecasting Madrigal Pharmaceuticals Inc. price range with options dataWeekly Stock Recap & Growth Focused Entry Reports - Newser
What momentum shifts mean for Madrigal Pharmaceuticals Inc.Market Movement Recap & Accurate Entry and Exit Point Alerts - Newser
Backtesting results for Madrigal Pharmaceuticals Inc. trading strategiesProfit Target & Low Risk High Win Rate Stock Picks - Newser
What to expect from Madrigal Pharmaceuticals Inc. in the next 30 daysQuarterly Growth Report & Consistent Profit Trading Strategies - Newser
Developing predictive dashboards with Madrigal Pharmaceuticals Inc. dataTrade Volume Report & Daily Technical Stock Forecast Reports - Newser
Published on: 2025-08-31 13:52:27 - Newser
Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here’s Why - MSN
How sentiment analysis helps forecast Madrigal Pharmaceuticals Inc.2025 Market Overview & Growth Focused Investment Plans - Newser
Madrigal Pharmaceuticals Inc. Shows Support at Fibonacci LevelQuarterly Trade Report & Free Low Drawdown Momentum Trade Ideas - beatles.ru
Earnings visualization tools for Madrigal Pharmaceuticals Inc.July 2025 Opening Moves & Safe Entry Point Alerts - Newser
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Madrigal Pharmaceuticals Inc-Aktie (MDGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sibold William John | President and CEO |
Aug 21 '25 |
Sale |
400.18 |
7,616 |
3,047,756 |
109,753 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):